200 related articles for article (PubMed ID: 27184892)
1. Clinical and economic impact of a specific BCG vaccination program implemented in Prato, central Italy, involving foreign newborns on hospitalizations.
Bellini I; Nastasi A; Boccalini S
Hum Vaccin Immunother; 2016 Sep; 12(9):2383-90. PubMed ID: 27184892
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui.
Lanckriet C; Lévy-Bruhl D; Bingono E; Siopathis RM; Guérin N
Int J Epidemiol; 1995 Oct; 24(5):1042-9. PubMed ID: 8557438
[TBL] [Abstract][Full Text] [Related]
3. Modelling the effect of discontinuing universal Bacillus Calmette-Guérin vaccination in an intermediate tuberculosis burden setting.
Fu H; Lin HH; Hallett TB; Arinaminpathy N
Vaccine; 2018 Sep; 36(39):5902-5909. PubMed ID: 30143270
[TBL] [Abstract][Full Text] [Related]
4. Bacillus Calmette-Guérin (BCG) vaccination patterns in the province of Québec, Canada, 1956-1974.
Rousseau MC; Conus F; Kâ K; El-Zein M; Parent MÉ; Menzies D
Vaccine; 2017 Aug; 35(36):4777-4784. PubMed ID: 28705514
[TBL] [Abstract][Full Text] [Related]
5. Impact of BCG vaccination on incidence of tuberculosis disease in southern Ireland.
Sweeney E; Dahly D; Seddiq N; Corcoran G; Horgan M; Sadlier C
BMC Infect Dis; 2019 May; 19(1):397. PubMed ID: 31072396
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of universal BCG vaccination of Japanese infants.
Rahman M; Sekimoto M; Takamatsu I; Hira K; Shimbo T; Toyoshima K; Fukui T
Int J Epidemiol; 2001 Apr; 30(2):380-5. PubMed ID: 11369746
[TBL] [Abstract][Full Text] [Related]
7. Non-specific effects of BCG vaccination on morbidity among children in Greenland: a population-based cohort study.
Haahr S; Michelsen SW; Andersson M; Bjorn-Mortensen K; Soborg B; Wohlfahrt J; Melbye M; Koch A
Int J Epidemiol; 2016 Dec; 45(6):2122-2130. PubMed ID: 28338723
[TBL] [Abstract][Full Text] [Related]
8. Economic Evaluation of Selective Neonatal Bacillus Calmette-Guérin Vaccination of High-risk Infants in Ireland.
Teljeur C; Moran PS; Harrington P; Butler K; Corcoran B; O'Donnell J; Usher C; O'Flanagan D; Connolly K; Ryan M
Pediatr Infect Dis J; 2018 Aug; 37(8):759-767. PubMed ID: 29432385
[TBL] [Abstract][Full Text] [Related]
9. BCG Vaccination at Birth and Rate of Hospitalization for Infection Until 15 Months of Age in Danish Children: A Randomized Clinical Multicenter Trial.
Stensballe LG; Ravn H; Birk NM; Kjærgaard J; Nissen TN; Pihl GT; Thøstesen LM; Greisen G; Jeppesen DL; Kofoed PE; Pryds O; Sørup S; Aaby P; Benn CS
J Pediatric Infect Dis Soc; 2019 Jul; 8(3):213-220. PubMed ID: 29635419
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guérin in Finland.
Hersh AL; Tala-Heikkilä M; Tala E; Tosteson AN; Fordham von Reyn C
Int J Tuberc Lung Dis; 2003 Jan; 7(1):22-9. PubMed ID: 12701831
[TBL] [Abstract][Full Text] [Related]
11. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices.
MMWR Recomm Rep; 1996 Apr; 45(RR-4):1-18. PubMed ID: 8602127
[TBL] [Abstract][Full Text] [Related]
12. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
13. Targeted BCG vaccination against severe tuberculosis in low-prevalence settings: epidemiologic and economic assessment.
Altes HK; Dijkstra F; Lugnèr A; Cobelens F; Wallinga J
Epidemiology; 2009 Jul; 20(4):562-8. PubMed ID: 19295437
[TBL] [Abstract][Full Text] [Related]
14. The lack of association between bacille Calmette-Guerin vaccination and clustering of Aboriginals with tuberculosis in western Canada.
Cook VJ; Hernández-Garduño E; Kunimoto D; Hershfield ES; Fanning EA; Hoeppner VH; Elwood RK; FitzGerald JM;
Can Respir J; 2005 Apr; 12(3):134-8. PubMed ID: 15875064
[TBL] [Abstract][Full Text] [Related]
15. BCG in Finland: changing from a universal to a selected programme.
Salo EP
Euro Surveill; 2006; 11(3):18-20. PubMed ID: 16567879
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of bacille Calmette-Guérin immunisation programs in Australia.
Khandaker G; Beard FH; Dey A; Coulter C; Hendry AJ; Macartney KK
Commun Dis Intell Q Rep; 2017 Mar; 41(1):E33-E48. PubMed ID: 28385137
[TBL] [Abstract][Full Text] [Related]
17. Is Bacillus Calmette-Guerin revaccination necessary for Japanese children?
Rahman M; Sekimoto M; Hira K; Koyama H; Imanaka Y; Fukui T
Prev Med; 2002 Jul; 35(1):70-7. PubMed ID: 12079443
[TBL] [Abstract][Full Text] [Related]
18. [Tuberculosis in Prato (Tuscany Region, Central Italy) in the period 2007-2014].
Bellini I; Pugi S; Degl'Innocenti C; Roselli A; Biagiotti D; Paliaga L; Berti C; Margheri V; Ricci L; Nastasi A
Epidemiol Prev; 2017; 41(5-6):256-260. PubMed ID: 29119760
[TBL] [Abstract][Full Text] [Related]
19. The rate of adverse events following BCG vaccination in Poland.
Krysztopa-Grzybowska K; Paradowska-Stankiewicz I; Lutyńska A
Przegl Epidemiol; 2012; 66(3):465-9. PubMed ID: 23230718
[TBL] [Abstract][Full Text] [Related]
20. Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK.
Mangtani P; Nguipdop-Djomo P; Keogh RH; Trinder L; Smith PG; Fine PE; Sterne J; Abubakar I; Vynnycky E; Watson J; Elliman D; Lipman M; Rodrigues LC
Health Technol Assess; 2017 Jul; 21(39):1-54. PubMed ID: 28738015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
